# MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)

> **NCT03721016** · PHASE3 · COMPLETED · sponsor: **Medy-Tox** · enrollment: 415 (actual)

## Conditions studied

- Glabellar Lines
- Lateral Canthal Lines

## Interventions

- **DRUG:** MT10109L
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03721016
- **Lead sponsor:** Medy-Tox
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-26
- **Primary completion:** 2020-03-05
- **Final completion:** 2021-01-22
- **Target enrollment:** 415 (ACTUAL)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03721016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03721016, "MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03721016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*